H.R. 1344 would amend the Public Health Service Act to authorize research and public health activities related to early detection, diagnosis, and treatment of hearing loss in newborns, infants, and young children. Those activities are conducted by the Health Resources and Services Administration (HRSA), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health (NIH).
CBO estimates that implementing H.R. 1344 would cost $212 million over the 2016-2020 period, assuming appropriation of the specified and necessary amounts. Enacting H.R. 1344 would not affect direct spending or revenues; therefore, pay-as-you-go procedures do not apply.
H.R. 1344 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act (UMRA).